Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL709514

CCOC(=O)c1cnc2[nH]c(-c3ccc(OC(C)C)cc3OC(C)C)nc2c1.O=C(O)C(F)(F)F

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
TP53 P04637 1/20 0.43
MAOB P27338 3/20 0.40
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRB1 P18505 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37
GABRB2 P47870 1/20 0.37
GABRA4 P48169 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10206500 0.94 MAPT (0.43) MAPTTP53MAOBKDM4EALDH1A1
Trifluoroacetic Acid SCHEMBL711644 0.93 MAPT (0.43) MAPTTP53MAOBKDM4EALDH1A1
Trifluoroacetic Acid SCHEMBL710837 0.92 MAOB (0.46) MAPTTP53MAOBALDH1A1HPGD
SCHEMBL10206497 0.86 MAOB (0.47) MAPTMAOBALDH1A1HPGDMEN1
SCHEMBL710777 0.86 MAPT (0.43) MAPTTP53MAOBALDH1A1MEN1
Trifluoroacetic Acid SCHEMBL710612 0.84 MAOB (0.49) MAPTMAOBALDH1A1HPGDMEN1
SCHEMBL710776 0.83 MCL1 (0.45) ALDH1A1KMT2AMCL1NPC1RAB9A
Trifluoroacetic Acid SCHEMBL712824 0.82 MCL1 (0.42) MEN1KMT2AMCL1HDAC3HDAC1
SCHEMBL710541 0.80 MAOB (0.47) MAPTMAOBALDH1A1HPGDMEN1
SCHEMBL711135 0.79 PKN1 (0.42) MAPTTP53MAOBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK MAPT 3003/4885TP53 4171/4885MAOB 1046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.